Investigating how WNT5a and ROR2 affect prostate cancer progression
WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate Cancer
This study is looking at how certain proteins, WNT5a and ROR2, affect the growth of prostate cancer, especially when it stops responding to regular treatments, to find new ways to help improve care for patients with advanced prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11101311 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of WNT5a and ROR2 in the progression of prostate cancer, particularly in cases where the cancer becomes resistant to standard treatments. The study aims to explore how these proteins influence the Hippo signaling pathway, which is involved in tumor growth and suppression. By examining the mechanisms of WNT signaling and its impact on cancer cell behavior, the research seeks to identify new therapeutic targets that could improve treatment outcomes for patients with advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic castration-resistant prostate cancer who have experienced treatment resistance.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone androgen deprivation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that enhance the effectiveness of therapies for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results in targeting WNT signaling pathways in cancer, indicating potential for success in this novel approach.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Balk, Steven P. — Beth Israel Deaconess Medical Center
- Study coordinator: Balk, Steven P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.